116 related articles for article (PubMed ID: 17133416)
1. Prostate-specific antigen nadir within 12 months of prostate cancer radiotherapy predicts metastasis and death.
Alcantara P; Hanlon A; Buyyounouski MK; Horwitz EM; Pollack A
Cancer; 2007 Jan; 109(1):41-7. PubMed ID: 17133416
[TBL] [Abstract][Full Text] [Related]
2. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer.
Abramowitz MC; Li T; Buyyounouski MK; Ross E; Uzzo RG; Pollack A; Horwitz EM
Cancer; 2008 Jan; 112(1):55-60. PubMed ID: 17968996
[TBL] [Abstract][Full Text] [Related]
3. Prostate-specific antigen nadir within 12 months as an early surrogate marker of biochemical failure and distant metastasis after low-dose-rate brachytherapy or external beam radiotherapy for localized prostate cancer.
Nishimura S; Ohashi T; Momma T; Sakayori M; Eriguchi T; Tanaka T; Yamashita S; Kosaka T; Oya M; Shigematsu N
Cancer Med; 2018 May; 7(5):1794-1801. PubMed ID: 29577651
[TBL] [Abstract][Full Text] [Related]
4. External beam radiotherapy for clinically localized hormone-refractory prostate cancer: clinical significance of Nadir prostate-specific antigen value within 12 months.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Shioyama Y; Araya M; Mukumoto N; Mitsumori M; Teshima T;
Int J Radiat Oncol Biol Phys; 2009 Jul; 74(3):759-65. PubMed ID: 19327908
[TBL] [Abstract][Full Text] [Related]
5. Postradiotherapy 2-year prostate-specific antigen nadir as a predictor of long-term prostate cancer mortality.
Zelefsky MJ; Shi W; Yamada Y; Kollmeier MA; Cox B; Park J; Seshan VE
Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1350-6. PubMed ID: 19515504
[TBL] [Abstract][Full Text] [Related]
6. Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer.
Hanlon AL; Diratzouian H; Hanks GE
Int J Radiat Oncol Biol Phys; 2002 Jun; 53(2):297-303. PubMed ID: 12023133
[TBL] [Abstract][Full Text] [Related]
7. Year of treatment as independent predictor of relapse-free survival in patients with localized prostate cancer treated with definitive radiotherapy in the PSA era.
Kupelian P; Thames H; Levy L; Horwitz E; Martinez A; Michalski J; Pisansky T; Sandler H; Shipley W; Zelefsky M; Zietman A; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(3):795-9. PubMed ID: 15925452
[TBL] [Abstract][Full Text] [Related]
8. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer.
Jacob R; Hanlon AL; Horwitz EM; Movsas B; Uzzo RG; Pollack A
Cancer; 2004 Feb; 100(3):538-43. PubMed ID: 14745870
[TBL] [Abstract][Full Text] [Related]
9. Postoperative radiotherapy for localized prostate cancer: clinical significance of nadir prostate-specific antigen value within 12 months.
Ogawa K; Nakamura K; Sasaki T; Onishi H; Koizumi M; Araya M; Mukumoto N; Mitsumori M; Teshima T;
Anticancer Res; 2009 Nov; 29(11):4605-13. PubMed ID: 20032410
[TBL] [Abstract][Full Text] [Related]
10. PSA nadir predicts biochemical and distant failures after external beam radiotherapy for prostate cancer: a multi-institutional analysis.
Ray ME; Thames HD; Levy LB; Horwitz EM; Kupelian PA; Martinez AA; Michalski JM; Pisansky TM; Shipley WU; Zelefsky MJ; Zietman AL; Kuban DA
Int J Radiat Oncol Biol Phys; 2006 Mar; 64(4):1140-50. PubMed ID: 16198506
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen doubling time predicts clinical outcome and survival in prostate cancer patients treated with combined radiation and hormone therapy.
Lee AK; Levy LB; Cheung R; Kuban D
Int J Radiat Oncol Biol Phys; 2005 Oct; 63(2):456-62. PubMed ID: 15927415
[TBL] [Abstract][Full Text] [Related]
12. Validation of a treatment policy for patients with prostate specific antigen failure after three-dimensional conformal prostate radiation therapy.
Pinover WH; Horwitz EM; Hanlon AL; Uzzo RG; Hanks GE
Cancer; 2003 Feb; 97(4):1127-33. PubMed ID: 12569615
[TBL] [Abstract][Full Text] [Related]
13. Interval to biochemical failure highly prognostic for distant metastasis and prostate cancer-specific mortality after radiotherapy.
Buyyounouski MK; Hanlon AL; Horwitz EM; Pollack A
Int J Radiat Oncol Biol Phys; 2008 Jan; 70(1):59-66. PubMed ID: 17919840
[TBL] [Abstract][Full Text] [Related]
14. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer.
D'Ambrosio DJ; Hanlon AL; Al-Saleem T; Feigenberg SJ; Horwitz EM; Uzzo RG; Pollack A; Buyyounouski MK
Int J Radiat Oncol Biol Phys; 2007 Mar; 67(4):1082-7. PubMed ID: 17241749
[TBL] [Abstract][Full Text] [Related]
15. A prostate specific antigen (PSA) bounce greater than 1.4 ng/mL Is clinically significant after external beam radiotherapy for prostate cancer.
Feigenberg SJ; Hanlon AL; Horwitz EM; Uzzo RG; Eisenberg D; Pollack A
Am J Clin Oncol; 2006 Oct; 29(5):458-62. PubMed ID: 17023779
[TBL] [Abstract][Full Text] [Related]
16. Short-term androgen deprivation and PSA doubling time: their association and relationship to disease progression after radiation therapy for prostate cancer.
Hanlon AL; Horwitz EM; Hanks GE; Pollack A
Int J Radiat Oncol Biol Phys; 2004 Jan; 58(1):43-52. PubMed ID: 14697419
[TBL] [Abstract][Full Text] [Related]
17. Biochemical failure as a determinant of distant metastasis and death in prostate cancer treated with radiotherapy.
Pollack A; Hanlon AL; Movsas B; Hanks GE; Uzzo R; Horwitz EM
Int J Radiat Oncol Biol Phys; 2003 Sep; 57(1):19-23. PubMed ID: 12909210
[TBL] [Abstract][Full Text] [Related]
18. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores.
Kupelian P; Katcher J; Levin H; Zippe C; Suh J; Macklis R; Klein E
Cancer J Sci Am; 1997; 3(2):78-87. PubMed ID: 9099457
[TBL] [Abstract][Full Text] [Related]
19. Defining biochemical failure after radiotherapy with and without androgen deprivation for prostate cancer.
Buyyounouski MK; Hanlon AL; Eisenberg DF; Horwitz EM; Feigenberg SJ; Uzzo RG; Pollack A
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1455-62. PubMed ID: 16169682
[TBL] [Abstract][Full Text] [Related]
20. PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer.
Roberts SG; Blute ML; Bergstralh EJ; Slezak JM; Zincke H
Mayo Clin Proc; 2001 Jun; 76(6):576-81. PubMed ID: 11393495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]